Amit Sahu, Sunny Rathee, Shivani Saraf, Sarjana Raikwar, Pooja Das Bidla, Rajesh Singh Pawar, Sanjay K. Jain
{"title":"来氟米特和白藜芦醇负载的纳米结构脂质载体原位水凝胶系统的开发和表征有效治疗类风湿性关节炎","authors":"Amit Sahu, Sunny Rathee, Shivani Saraf, Sarjana Raikwar, Pooja Das Bidla, Rajesh Singh Pawar, Sanjay K. Jain","doi":"10.1007/s12247-025-09976-5","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>This study aims to improve the therapeutic effect of leflunomide (LEF), an immune-altering drug, and resveratrol (RSV), a polyphenolic compound distributed locally in the body. LEF and RSV were encapsulated in nanostructured lipid carriers (NLCs).</p><h3>Method </h3><p>NLCs were prepared by modified thermal homogenization and melt sonication using compritol ATO 888, oleic acid, Tween 80, and PEG 400. A Box-Behnken design (BBD) was utilized to optimize the formulation. The ideal NLC surface was modified by conjugation with chondroitin sulfate (CHS). Chondroitin sulfate-modified NLCs dispersions (CHS-NLCs) were characterized by particle size, PDI, encapsulation efficiency, and zeta potential. Thermosensitive gel was prepared using Pluronic F-127 (PF-127) and Pluronic F-68 (PF-68). Gels prepared in situ based on CHS-NLCs were characterized by gel time, thermal reversibility, pH, viscosity, injection time, and in vitro release. The effectiveness of the NLC-based in situ hydrogels was tested in an arthritis model.</p><h3>Results </h3><p>The produced CHS-NLCs had a particle size of 188.2 ± 0.85 nm, PDI of 0.396 ± 0.005, zeta potential of -17.16 ± 0.81 mV, LEF and RSV encapsulation efficiency of 92.16 ± 0.41 and 82.82%, respectively. The gel was thermosensitive and released 79.54% and 76.99% of LEF and RSV, respectively, within 144 h. The effectiveness of the proposed method was tested using an arthritis model, and the results showed a reduction in joint pain in mice in 21 days.</p><h3>Conclusion </h3><p>The developed CHS-modified NLC-based in situ hydrogel demonstrated effective, sustained drug release and significant therapeutic benefits in an RA model. This approach holds promise for improved RA management through localized drug delivery.</p><h3>Graphical Abstract</h3><p>Figure: Leflunomide and resveratrol-loaded nanostructured lipid carrier-based in-situ hydrogel system for effective management of Rheumatoid Arthritis</p>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 3","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development and Characterization of Leflunomide and Resveratrol Loaded Nanostructured Lipid Carrier Based In-situ Hydrogel System for Effective Management of Rheumatoid Arthritis\",\"authors\":\"Amit Sahu, Sunny Rathee, Shivani Saraf, Sarjana Raikwar, Pooja Das Bidla, Rajesh Singh Pawar, Sanjay K. Jain\",\"doi\":\"10.1007/s12247-025-09976-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>This study aims to improve the therapeutic effect of leflunomide (LEF), an immune-altering drug, and resveratrol (RSV), a polyphenolic compound distributed locally in the body. LEF and RSV were encapsulated in nanostructured lipid carriers (NLCs).</p><h3>Method </h3><p>NLCs were prepared by modified thermal homogenization and melt sonication using compritol ATO 888, oleic acid, Tween 80, and PEG 400. A Box-Behnken design (BBD) was utilized to optimize the formulation. The ideal NLC surface was modified by conjugation with chondroitin sulfate (CHS). Chondroitin sulfate-modified NLCs dispersions (CHS-NLCs) were characterized by particle size, PDI, encapsulation efficiency, and zeta potential. Thermosensitive gel was prepared using Pluronic F-127 (PF-127) and Pluronic F-68 (PF-68). Gels prepared in situ based on CHS-NLCs were characterized by gel time, thermal reversibility, pH, viscosity, injection time, and in vitro release. The effectiveness of the NLC-based in situ hydrogels was tested in an arthritis model.</p><h3>Results </h3><p>The produced CHS-NLCs had a particle size of 188.2 ± 0.85 nm, PDI of 0.396 ± 0.005, zeta potential of -17.16 ± 0.81 mV, LEF and RSV encapsulation efficiency of 92.16 ± 0.41 and 82.82%, respectively. The gel was thermosensitive and released 79.54% and 76.99% of LEF and RSV, respectively, within 144 h. The effectiveness of the proposed method was tested using an arthritis model, and the results showed a reduction in joint pain in mice in 21 days.</p><h3>Conclusion </h3><p>The developed CHS-modified NLC-based in situ hydrogel demonstrated effective, sustained drug release and significant therapeutic benefits in an RA model. This approach holds promise for improved RA management through localized drug delivery.</p><h3>Graphical Abstract</h3><p>Figure: Leflunomide and resveratrol-loaded nanostructured lipid carrier-based in-situ hydrogel system for effective management of Rheumatoid Arthritis</p>\\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>\",\"PeriodicalId\":656,\"journal\":{\"name\":\"Journal of Pharmaceutical Innovation\",\"volume\":\"20 3\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Innovation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12247-025-09976-5\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-09976-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Development and Characterization of Leflunomide and Resveratrol Loaded Nanostructured Lipid Carrier Based In-situ Hydrogel System for Effective Management of Rheumatoid Arthritis
Purpose
This study aims to improve the therapeutic effect of leflunomide (LEF), an immune-altering drug, and resveratrol (RSV), a polyphenolic compound distributed locally in the body. LEF and RSV were encapsulated in nanostructured lipid carriers (NLCs).
Method
NLCs were prepared by modified thermal homogenization and melt sonication using compritol ATO 888, oleic acid, Tween 80, and PEG 400. A Box-Behnken design (BBD) was utilized to optimize the formulation. The ideal NLC surface was modified by conjugation with chondroitin sulfate (CHS). Chondroitin sulfate-modified NLCs dispersions (CHS-NLCs) were characterized by particle size, PDI, encapsulation efficiency, and zeta potential. Thermosensitive gel was prepared using Pluronic F-127 (PF-127) and Pluronic F-68 (PF-68). Gels prepared in situ based on CHS-NLCs were characterized by gel time, thermal reversibility, pH, viscosity, injection time, and in vitro release. The effectiveness of the NLC-based in situ hydrogels was tested in an arthritis model.
Results
The produced CHS-NLCs had a particle size of 188.2 ± 0.85 nm, PDI of 0.396 ± 0.005, zeta potential of -17.16 ± 0.81 mV, LEF and RSV encapsulation efficiency of 92.16 ± 0.41 and 82.82%, respectively. The gel was thermosensitive and released 79.54% and 76.99% of LEF and RSV, respectively, within 144 h. The effectiveness of the proposed method was tested using an arthritis model, and the results showed a reduction in joint pain in mice in 21 days.
Conclusion
The developed CHS-modified NLC-based in situ hydrogel demonstrated effective, sustained drug release and significant therapeutic benefits in an RA model. This approach holds promise for improved RA management through localized drug delivery.
Graphical Abstract
Figure: Leflunomide and resveratrol-loaded nanostructured lipid carrier-based in-situ hydrogel system for effective management of Rheumatoid Arthritis
期刊介绍：
The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories:
Materials science,
Product design,
Process design, optimization, automation and control,
Facilities; Information management,
Regulatory policy and strategy,
Supply chain developments ,
Education and professional development,
Journal of Pharmaceutical Innovation publishes four issues a year.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
